Klinik Psikofarmakoloji Bülteni, Cilt: 14, Say›: 1, 2004 /
Bulletin of Clinical Psychopharmacology, Vol: 14, N.: 1, 2004 - www.psikofarmakoloji.org
37
19. Vieta E, Goikolea JM, Olivares JM, Gonzalez-Pinto A, Rodriguez A,
Colom F, Comes M, Torrent C, Sanchez-Moreno J. 1-year follow-up
of patients treated with risperidone and topiramate for a manic
episode. J Clin Psychiatry 2003;64:834-839
20. Chengappa KN, Gershon S, Levine J. The evolving role of
topiramate among other mood stabilizers in the management of
bipolar disorder. Bipolar Disord 2001;3:215-232
21. Malcolm R, Myrick H, Brady KT, Ballenger JC. Update on
anticonvulsants for the treatment of alcohol withdrawal. Am J
Addict 2001;10(Suppl):16-23
22. Rasmussen K. The role of the locus coeruleus and N-methyl-D-
aspartic acid (NMDA) and AMPA receptors in opiate withdrawal.
Neuropsychopharmacology 1995;13:295-300
23. Rasmussen K, Kendrick WT, Kogan JH, Aghajanian GK. A selective
AMPA antagonist, LY293558, suppresses morphine with-
drawaliduced activation of locus coeruleus neurons and behavioral
signs of morphine withdrawal. Neuropsychopharmacology
1996;15:497-505
24. Jackson A, Mead AN, Stephens DN. Behavioural effects of
alphaamino-3-hydroxy-5-methyl-4-isoxazolepropionate-receptor
antagonists and their relevance to substance abuse. Pharmacol
Ther 2000;88:59-76
25. Zullino DF, Krenz S, Kolly S, Favrat B, Zimmermann G, Simon O,
Benson J. Topiramate vs. clonidine vs. carbamazepine/mianser-
ine in opiate withdrawal. Poster presented at 11th Congress of the
European Psychiatrists. Stockholm, Sweden, 4-8 May, 2002.
26 Zullino DF, Cottier AC, Besson J. Topiramate in opiate withdrawal.
Progress in Neuropsychopharmacology Biological Bsychiatry
2002;26:1221-1223
27. Bertschy G, Bryois C, Bondolfi G, Velardi A, Budry P, Dascal D,
Martinet C, Baettig D, Baumann P. The association
carbamazepine-mianserin in opiate withdrawal: a double blind
pilot study versus clonidine. Pharmacol Res 1997;35:451-456
28. Schmidt do Prado-Lima PA. Topiramate in the treatment of cannabis
dependence in a schizoaffective patient. Poster presented at XIth
World Congress of Psychiatry. Hamburg, Germany, 6-11 August, 1999
29. Schiffer WK, Gerasimov MR, Marsteller DA, Geiger J, Barnett C,
Alexoff DL, Dewey SL. Topiramate selectively attenuates
nicotine-induced increases in monoamine release. Synapse
2001;42:196-198
30. Schilstrom B, Nomikos GG, Nisell M, Hertel P, Svensson TH.
N-methyl-D-aspartate receptor antagonism in the ventral tegmental
area diminishes the systemic nicotine-induced dopamine release
in the nucleus accumbens. Neuroscience 1998;82:781-789
31. Chen Z, Engberg G. The rat nucleus paragigantocellularis as a
relay station to mediate peripherally induced central effects of
nicotine. Neurosci Lett 1989;101:67-71
32. Erhardt S, Hajos M, Lindberg A, Engberg G. Nicotine-induced
excitation of locus coeruleus neurons is blocked by elevated levels
of endogenous kynurenic acid. Synapse 2000;37:104-108
33. Corrigall WA, Coen KM, Adamson KL, Chow BL, Zhang J.
Response of nicotine self-administration in the rat to
manipulations of mu-opioid and gamma-aminobutyric acid
receptors in the ventral tegmental area. Psychopharmacology
(Berl) 2000;149:107-114
34. Gilron I, Booher SL, Rowan JS, Max MB. Topiramate in trigeminal
neuralgia: a randomized, placebo-controlled multiple crossover
pilot study. Clin Neuropharmacol 2001;24:109-112
35. Mathew NT, Kailasam J, Meadors L. Prophylaxis of migraine,
transformed migraine, and cluster headache with topiramate.
Headache 2002;42:796-803
36. Garcia-Campayo J, Sanz-Carillo C. Topiramate as a treatment for
pain in multisomatoform disorder patients: an open trial. Gen
Hosp Psychiatry 2002;24:417-421
37. Schmidt do Prado-Lima PA, Bacalthuck J. Topiramate in treatment
resistant depression and binge eating disorder. Bipolar Disord
2002;4:271-273
38. McElroy SL, Arnold LM, Shapira NA, Keck PE, Rosenthal NR, Karim
MR, Kamin M, Hudson JI. Topiramate in the treatment of
binge-eating disorder associated with obesity: a randomized,
placebo-controlled trial. Am J Psychiatry 2003;160:255-261
39. Dannon PN. Topiramate for the treatment of kleptomania: a case
series and review of the literature. Clin Neuropharmacol 2003;
26:1-4
40. Berlant J, van Kammen DP. Open-label topiramate as primary or
adjunctive therapy in chronic civilian posttraumatic stress disorder:
a preliminary report. J Clin Psychiatry 2002;63:15-20
41. Crawford P. An audit of topiramate use in a general neurology
clinic. Seizure 1998;7:207-211
42. Martin R, Kuzniecky R, Hetherington H, Pan J, Sinclair K, Gilliam F,
Puaght E. Cognitive effects of topiramate, gabapentin, and
lamotrigine in healthy young adults. Neurology 1999;52:321-327
43. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U.
Predictors of weight loss in adults with topiramate-treated
epilepsy. Obes Res 2003;11:556-562
44. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of
topiramate in the regulation of energy balance. Nutrition
2000;16:961-966
O. Karamustafal›o¤lu, S. Demirk›ran